International E-publication: Publish Projects, Dissertation, Theses, Books, Souvenir, Conference Proceeding with ISBN.  International E-Bulletin: Information/News regarding: Academics and Research

Role of High Sensitivity C Reactive Protein and Interleukin -6 in Cardiovascular Disease

Author Affiliations

  • 1 Sri Aurobindo Institute of Medical Sciences, Indore, 452015, Madhya Pradesh, INDIA
  • 2 Mahatma Gandhi Memorial Medical College, Indore, 452001, Madhya Pradesh, INDIA
  • 3 Index Medical College Hospital and Research Centre, Indore, 452016, Madhya Pradesh, INDIA

Int. Res. J. Medical Sci., Volume 2, Issue (12), Pages 4-8, December,28 (2014)


The study comprised of 100 patients with known history of CVD compared with 100 control healthy subjects. We investigated the levels of fasting lipid profile and inflammatory markers as hs C-reactive protein and interleukin-6 in patients with cardiovascular disease andcompared with control subjects. The fasting lipid profile were found significantly raised (p0.0001) except HDL-C in CVD patients than control subjects. The levels of serum hs CRP and IL-6 were also found significantly higher (p0.0001) in cardiovascular disease compared to control subjects.In conclusion, measurement of C-reactive protein and interleukin-6 may be useful in predicting a patient’s risk of future cardiovascular events.


  1. Alexander R.W., Inflammation and coronary arterydisease, N. Engl. J. Med., 331, 468–9 (1994)
  2. Ali V., Pinkney J.H., Coppack S.W., Adipose tissue as anendocrine and paracrine organ, Int. J. Obesity, 22, 1145-1158 (1998)
  3. Tracy R.P., Lemaitre R.N. and Psaty B.M. et al.,Relationship of C-reactive protein to risk ofcardiovascular disease in the elderly, Arterioscler.Thromb. Vasc. Biol., 17, 1121–1127 (1997)
  4. Harris T.B., Ferrucci L. and Tracy R.P. et al.,Associations of elevated interleukin-6 and C-reactiveprotein levels with mortality in the elderly, Am. J. Med.,106, 506–512 (1999)
  5. Koenig W. and Khuseyinova N., Biomarkers ofatherosclerotic plaque instability and rupture.Arterioscler. Thromb. Vascu. Biol., 27, 15-26 (2007)
  6. Papanicolaou D.A., Wilder R.L., Manolagas S.C. andChrousos G.P., The pathophysiologic roles ofinterleukin-6 in human disease. Ann. Intern. Med., 28,127-137(1998)
  7. Ridker P.M., Hennekens C.H., Buring J.E. and Rifai N.,C-reactive protein and other markers of inflammation inthe prediction of cardiovascular disease in women, N.Engl. J. Med., 342, 836-843 (2000)
  8. Bennet A.M., Prince J.A., Fei G.Z., Lyrenas L. andHuang Y. et al., Interleukin-6 serum levels and genotypesinfluence the risk for myocardial infarction,Atherosclerosis, 171, 359-367 (2003)
  9. Liuzzo G., Baisucci L.M. and Gallimore J.R. et al.,Enhanced inflammatory response in patients with preinfarction unstable angina, J. Am. Coll. Cardiol.,34,1696–1703 (1999)
  10. Biasucci L.M., Liuzzo G. and Fantuzzi G. et al.,Increasing levels of interleukin (IL)-1Ra and IL-6 duringthe first 2 days of hospitalization in unstable angina areassociated with increased risk of in-hospital coronaryevents, Circulation, 99, 2079–2084 (1999)
  11. Danesh J., Kaptoge S., Mann A.G., Sarwar N. and WoodA. et al., Long-term interleukin-6 levels and subsequentrisk of coronary heart disease: Two new prospectivestudies and a systematic review, PLoS Med., 5, e78(2008)
  12. Fisman E.Z., Benderly M., Esper R.J., Behar S. andBoyko V. et al., Interleukin-6 and the risk of futurecardiovascular events in patients with angina pectorisand/ or healed myocardial infarction, Am. J. Cardiol., 98,14-18 (2006)
  13. Maeda K., Tsutamoto T., Wada A., Mabuchi N. andHayashi M. et al., High levels of plasma brain natriureticpeptide and interleukin-6 after optimized treatment forheart failure are independent risk factors for morbidityand mortality in patients with congestive heart failure, J.Am. Coll. Cardiol., 36, 1587- 1593 (2000)
  14. Mesri M. and Altieri D.C., Endothelial cell activation byleukocyte micro particles, J. Immunol., 161, 4382-7(1998)
  15. Xin X., Cai Y., Matsumoto K. and Agui T., Endothelininducedinterleukin-6 production by rat aortic endothelialcells, Endocrinology, 136, 132-137 (1995)
  16. Baba T., Uchimura I., Fujisawa K., Morohoshi M. andAsaoka H. et al., Production of interleukin-6 induced byhypoxia linked to peripheral arterial disease, Ann. N. Y.Acad. Sci., 811, 542-548 (1997)
  17. Tsuji H., Larson M.G., Venditti F.J., Manders E.S. andEvans J.C. et al., Impact of reduced heart rate variabilityon risk for cardiac events, The framingham heart study,Circulation, 94, 2850-2855 (1996)
  18. Rovere M.T., Bigger J.T., Marcus F.I., Mortara A. andSchwartz P.J., Baroreflex sensitivity and heart-ratevariability in prediction of total cardiac mortality aftermyocardial infarction, Atrami (autonomic tone andreflexes after myocardial infarction) investigators,Lancet, 351, 478-484 (1998)
  19. Gwechenberger M., Mendoza L.H. and Youker K.A. etal., Cardiac myocytes produce interleukin-6 in cultureand in viable border zone of re-perfused infarctions,Circulation, 99, 546-51(1999)
  20. Liuzzo G., Buffon A. and Biasucci L.M., Enhancedinflammatory response to coronary angioplasty in patients with severe unstable angina, Circulation, 98,2370–2376 (1998)
  21. Abdelmouttaleb I., Danchin N. and Ilardo C. et al., Creactive protein and coronary artery disease: additional evidence of the implication of an inflammatory process in acute coronary syndromes, Am. Hrt. J., 137, 346–351 (1999)
  22. Lagrand W.K., Visser C.A. and Hermens W.T. et al., Creactiveprotein and cardiovascular risk factor: more thanan epiphenomenon?, Circulation,100, 96–102 (1999)
  23. Pasceri V., WillersonJ.T. and Yeh E.T., Direct proinflammatoryeffect of C-reactive protein on humanendothelial cells, Circulation,102, 2165–2168 (2000)